Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of the American College of Cardiology

• Publication date

  2014-07-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacc.2014.03.051PMID 25060370PMCID PMC11284982
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.

  2013cited by this paper
• Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.

  2013cited by this paper
• A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem

  2012cited by this paper
• 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary

  2012cited by this paper
• Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease

  2012cited by this paper
• Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention: The GRAVITAS Randomized Trial

  2012cited by this paper
• Bedside monitoring to adjust antiplatelet therapy for coronary stenting.

  2012cited by this paper
• Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

  2011influential reference
• Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay Impact on Thrombosis and Safety (GRAVITAS) Trial

  2011cited by this paper
• Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

  2011cited by this paper
• ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions

  2011cited by this paper
• 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in c

  2011cited by this paper
• Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome.

  2011cited by this paper
• 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in

  2011influential reference
• Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.

  2011cited by this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cited by this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cited by this paper
• Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

  2010cited by this paper
• Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients

  2010cited by this paper
• Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

  2010cited by this paper
• Platelet aggregation responses vary over a period of time in healthy controls

  2010cited by this paper
• Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.

  2010cited by this paper
• Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.

  2009cited by this paper
• Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay: A 12-Month Follow-Up

  2009cited by this paper
• The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study.

  2008cited by this paper
• Antiplatelet response to the 150-mg maintenance dose of clopidogrel in patients with insufficient platelet inhibition after clopidogrel loading for elective coronary stent placement.

  2008cited by this paper
• Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.

  2008cited by this paper
• A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days.

  2008cited by this paper
• The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score

  2007cited by this paper
• Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study

  2007cited by this paper
• Reproducibility of platelet function testing.

  2007cited by this paper
• Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment.

  2006cited by this paper
• Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.

  2006cited by this paper
• Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention

  2005cited by this paper
• Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity

  2003cited by this paper

• Overcoming Clopidogrel Resistance in Carotid Artery Stenting: Experience with Ticagrelor and Ticlopidine.

  2026influential citation
• The Relationship Between Biological Noise and Its Application: Understanding System Failures and Suggesting a Method to Enhance Functionality Based on the Constrained Disorder Principle

  2025cites this paper
• Risk factors for new ischaemic lesions on MR DWI after carotid stenting in patients with efficient antiplatelet therapy

  2025cites this paper
• Platelet Reactivity and Fibrin Clot-Strength as assessed by TEG in Patients with Atrial Fibrillation undergoing Percutaneous Coronary Intervention

  2025cites this paper
• Low on-clopidogrel ADP- and TRAP-6-induced platelet aggregation in patients with atrial fibrillation undergoing percutaneous coronary intervention: an observational pilot study

  2024cites this paper
• Perioperative platelet reactivity over time in patients undergoing vascular surgery: An observational pilot study

  2024cites this paper
• Platelet-fibrin clot strength and platelet reactivity predicting cardiovascular events after percutaneous coronary interventions.

  2024cites this paper
• THE ANATOLIAN JOURNAL OF CARDIOLOGY

  2023cites this paper
• Platelet function testing - a single centre experience

  2023cites this paper
• Guided Anti-P2Y 12 Therapy in Patients Undergoing Percutaneous Coronary Intervention

  2023cites this paper
• Impact of the Xinsorb Scaffold-Related Parameters on Platelet Reactivity in Patients with Single De Novo Coronary Artery Lesions Undergoing Clopidogrel Treatment

  2023cites this paper
• Guided Anti-P2Y12 Therapy in Patients Undergoing PCI: Three Systematic Reviews with Meta-analyses of Randomized Controlled Trials with Homogeneous Design

  2023cites this paper
• Guided antiplatelet therapy with P2Y12 antagonists in patients undergoing percutaneous coronary intervention: 3 systematic reviews with meta-analyses of randomized controlled trials with homogeneous design

  2023cites this paper
• Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention.

  2023cites this paper
• Development and Validation of a Novel Tool for the Prediction of Clopidogrel Response in Chinese Acute Coronary Syndrome Patients: The GeneFA Score

  2022cites this paper
• The role of mechanical valves in the aortic position in the era of bioprostheses and TAVR: Evidence-based appraisal and focus on the On-X valve.

  2022cites this paper
• Platelet FcγRIIa Expression in Ischemic Stroke: A Marker of Increased Platelet Reactivity

  2022cites this paper
• Clinical Outcomes After Percutaneous Coronary Intervention Over Time on the Basis of CYP2C19 Polymorphisms

  2021cites this paper
• Multi-institutional patterns of clopidogrel response among patients undergoing transcarotid artery revascularization

  2021cites this paper
• Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity: Analysis From ADAPT-DES.

  2021cites this paper
• Clinical importance of testing for clopidogrel resistance in patients undergoing carotid artery stenting—a systematic review

  2021cites this paper
• Endothelial Shear Stress and Platelet FcγRIIa Expression in Intracranial Atherosclerotic Disease

  2021cites this paper
• P2Y12 inhibitors in neuroendovascular surgery: An opportunity for precision medicine

  2021cites this paper
• CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls

  2020cites this paper
• Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke

  2020cites this paper
• Antiplatelet Therapy in Secondary Prevention in Patients with Ischaemic Peripheral Arterial Disease

  2020cites this paper
• The Role of Platelet Function Testing in Improving Clinical Outcomes

  2020cites this paper
• Clinical significance of high on-treatment platelet reactivity in patients with prolonged clopidogrel therapy

  2020cites this paper
• Reticulated Platelets in Medicine: Current Evidence and Further Perspectives

  2020cites this paper
• Variation in platelet expression of FcγRIIa after myocardial infarction

  2019cites this paper
• Laboratory Monitoring of Antiplatelet Therapy

  2019cites this paper
• Temporal Variability of Platelet Reactivity in Patients Treated with Clopidogrel or Ticagrelor

  2019cites this paper
• Temporal Variability of Platelet Reactivity Phenotype: Another Barrier to Personalized Antiplatelet Strategy Guided by Platelet Function Testing

  2019cites this paper
• The Efficacy of P2Y12 Reactive Unit to Predict the Periprocedural Thromboembolic and Hemorrhagic Complications According to Clopidogrel Responsiveness and Safety of Modification of Dual Antiplatelet Therapy : A Meta-Analysis

  2019cites this paper
• Assessment of Cardiovascular Risk by the Combination of Clinical Risk Scores Plus Platelet Expression of FcγRIIa.

  2019cites this paper
• CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis

  2019cites this paper
• Cardiovascular Risk Reduction: A Pharmacotherapeutic Update for Antiplatelet Medications.

  2019cites this paper
• Pharmacodynamic changes of platelet reactivity status in patients with chronic kidney disease after coronary artery stenting.

  2019cites this paper
• Platelet Function Testing in Clinical Research Trials

  2019cites this paper
• Genetic and Molecular Testing in Thrombosis and Hemostasis: Informing Surveillance, Treatment, and Prognosis

  2019cites this paper
• Precision of VerifyNow P2Y12 Assessment of Clopidogrel Response in Patients Undergoing Cerebral Aneurysm Flow Diversion.

  2018cites this paper
• Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI

  2018cites this paper
• Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine

  2018cites this paper
• Clinical Significance of Acute and Serial Platelet Function Testing in Acute Ischemic Stroke

  2018cites this paper
• Individual long-term variation of platelet reactivity in patients with dual antiplatelet therapy after myocardial infarction.

  2018cites this paper
• Thrombin generation and platelet activation in cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy - A prospective cohort study

  2018cites this paper
• Mass Cytometry Reveals Distinct Platelet Subtypes in Healthy Subjects and Novel Alterations in Surface Glycoproteins in Glanzmann Thrombasthenia

  2018cites this paper
• Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve Replacement.

  2018cites this paper
• FcγRIIa: A New Cardiovascular Risk Marker.

  2018cites this paper
• Personalizing antiplatelet therapies: What have we learned from recent trials?

  2018cites this paper
• Incomplete Revascularization: The Achilles Heel of Percutaneous Coronary Interventions.

  2017cites this paper
• How I use laboratory monitoring of antiplatelet therapy.

  2017cites this paper
• Temporal Changes in Platelet Response in Acute Coronary Syndrome Patients With Prasugrel and Clopidogrel After Stent Implantation.

  2017cites this paper
• Reply: Platelet Reactivity: Journey to the End of the Night.

  2017cites this paper
• Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study).

  2017cites this paper
• An Unresolved Question: Antiplatelet Treatment Driven by Platelet Function in ST-Segment Elevation Myocardial Infarction Patients.

  2017cites this paper
• Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors

  2017cites this paper
• Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents)

  2017cites this paper
• The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics

  2017cites this paper
• Prediction of high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndromes.

  2017cites this paper
• A Reappraisal of Anterior Communicating Artery Aneurysms: A Case for Stent-Assisted Embolization.

  2016cites this paper
• Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel.

  2016cites this paper
• P2Y12 Reaction Units: Effect on Hemorrhagic and Thromboembolic Complications in Patients With Cerebral Aneurysms Treated With the Pipeline Embolization Device.

  2016cites this paper
• Platelet function testing as a biomarker for efficacy of antiplatelet drugs.

  2016cites this paper
• Associations of P 2 Y 12 R Gene Polymorphisms with Susceptibility to Coronary Heart Disease and Clinical Efficacy of Antiplatelet Treatment with Clopidogrel Running title : Associations of SNPs in the P 2 Y 12 R gene with CHD

  2016cites this paper
• Changes in response to clopidogrel therapy in patients after percutaneous coronary interventions as assessed by different platelet function tests

  2016cites this paper
• The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway

  2016cites this paper
• Changes in response to clopidogrel therapy in patients after percutaneous coronary interventions as assessed by different platelet function tests.

  2016cites this paper
• Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial

  2016cites this paper
• Efficacy of a two-test protocol for achieving a therapeutic response to clopidogrel prior to elective endovascular intracranial aneurysm treatment and an ‘induced’ postoperative hyper-response

  2016cites this paper
• Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical Practitioner

  2016cites this paper
• The Importance of the Mean Platelet Aggregation Degree in Long-term Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation.

  2016cites this paper
• Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on‐treatment platelet reactivity

  2016cites this paper
• Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study

  2016cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel

  2015cites this paper
• Review of clopidogrel dose escalation in the current era of potent P2Y12 inhibitors

  2015cites this paper
• Clopidogrel Response Variability: Etiology and Clinical Relevance

  2015cites this paper
• Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation

  2015influential citation
• Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study

  2015cites this paper
• Clopidogrel: A multifaceted affair

  2015cites this paper
• Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.

  2015cites this paper
• A time course study of high on treatment platelet reactivity in acute coronary syndrome male patients on dual antiplatelet therapy.

  2015cites this paper
• Antiplatelet Efficacy of Fixed-Dose Aspirin–Clopidogrel Combination in Patients with Stable Coronary Artery Disease Treated with Drug-Eluting Stent Implantation

  2015cites this paper
• CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis

  2015cites this paper
• Clinical Implications of Changes in Individual Platelet Reactivity to Aspirin Over Time in Acute Ischemic Stroke

  2015cites this paper
• Defining the link between chronic kidney disease, high platelet reactivity, and clinical outcomes in clopidogrel-treated patients undergoing percutaneous coronary intervention.

  2015cites this paper
• The chronovariability of platelet reactivity: a hurdle in the road to personalized antiplatelet therapy?

  2014cites this paper